Show simple item record

dc.contributor.authorGrimes, Seamus
dc.contributor.authorMiozzo, Marcela
dc.date.accessioned2017-04-13T14:48:18Z
dc.date.available2017-04-13T14:48:18Z
dc.date.issued2015-04-18
dc.identifier.citationGrimes, Seamus, & Miozzo, Marcela. (2015). Big Pharma's Internationalization of R&D to China. European Planning Studies, 23(9), 1873-1894. doi: 10.1080/09654313.2015.1029442en_IE
dc.identifier.issn1469-5944
dc.identifier.urihttp://hdl.handle.net/10379/6440
dc.description.abstractChina's increasing integration into the global pharmaceutical value chain is occurring at a time when big pharma's traditional R&D model has entered a period of crisis, and when China faces significant challenges in providing healthcare for its huge and rapidly ageing population. Despite China's ambitions of promoting its own pharmaceutical sector, it is likely to continue to depend for some time on significant contributions from foreign companies. While this situation provides considerable opportunities for big pharma companies to expand their markets in China, they are also hoping that offshoring aspects of their R&D to China may contribute to reconfiguring their current R&D model with its weak record of producing new drugs. Drawing on interviews with a small number of pharma R&D centres in Shanghai, patent analyses and industry reports, we provide insights into both the challenges and the opportunities associated with the early stages of establishing such centres in an emerging region with a rapidly growing market. This paper contributes towards a more nuanced view of the internationalization of R&D in emerging regions.en_IE
dc.description.sponsorshipThis research has been supported by the Institute of China Innovation at East China Normal University, Shanghai.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherTaylor & Francisen_IE
dc.relation.ispartofEuropean Planning Studiesen
dc.subjectChinaen_IE
dc.subjectPharmaceutical sectoren_IE
dc.subjectGlobalizing innovationen_IE
dc.subjectForeign R&D centresen_IE
dc.subjectInnovationen_IE
dc.subjectGlobalizationen_IE
dc.subjectTechnologyen_IE
dc.subjectStrategiesen_IE
dc.subjectManagementen_IE
dc.subjectTaxonomyen_IE
dc.subjectIndiaen_IE
dc.titleBig Pharma's internationalization of R&D to Chinaen_IE
dc.typeArticleen_IE
dc.date.updated2017-04-03T16:45:49Z
dc.identifier.doi10.1080/09654313.2015.1029442
dc.local.publishedsourcehttp://dx.doi.org/10.1080/09654313.2015.1029442en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funder|~|
dc.internal.rssid9392102
dc.local.contactSéamus Grimes, School Of Geography& Archaeology, & Whitaker Institute, Room 124 Arts/Science Building, Nui Galway. 2636 Email: seamus.grimes@nuigalway.ie
dc.local.copyrightcheckedNo
dc.local.versionPUBLISHED
nui.item.downloads401


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record